Drugs / RJV001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04821648 | Apr → Dec 2021 | — | Rejuven Dermaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RJV001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04821648 ↗ |
| Modality | Protein / enzyme biologic | “RJV001 is a mutant recombinant collagenase of Clostridium histolyticum” NCT04821648 ↗ |
| Route | Subcutaneous | “Subcutaneous injection in the abdomen” NCT04821648 ↗ |